SCHEMBL136247

SCHEMBL136247

COc1ccc2nc(Nc3cc(C(F)(F)c4ccc(F)cc4)nc(Cl)n3)sc2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 8/20 0.67
ITK Q08881 7/20 0.67
AURKB Q96GD4 6/20 0.47
HCK P08631 1/20 0.35
BTK Q06187 1/20 0.35
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
NPC1 O15118 2/20 0.32
SCD O00767 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 2/20 0.32
MAPT P10636 2/20 0.32
HTT P42858 2/20 0.32
MCL1 Q07820 2/20 0.32
TNF P01375 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
NR2F2 P24468 1/20 0.32
KLF5 Q13887 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141486 0.83 LCK (0.67) LCKITKAURKBMEN1KMT2A
SCHEMBL141010 0.80 ITK (1.00) LCKITKAURKBBTKIRAK4
SCHEMBL141011 0.80 ITK (1.00) LCKITKAURKBBTKIRAK4
SCHEMBL139156 0.79 LCK (0.63) LCKITKAURKBGAABUB1
SCHEMBL143889 0.77 LCK (0.49) LCKITKAURKBMEN1KMT2A
SCHEMBL138176 0.77 LCK (0.55) LCKITKAURKBMEN1KMT2A
SCHEMBL140313 0.77 LCK (0.55) LCKITKAURKBMEN1KMT2A
SCHEMBL143491 0.72 LCK (0.49) LCKITKAURKBHCKBTK
SCHEMBL138318 0.68 LCK (0.66) LCKITKAURKBHCKBTK
SCHEMBL144539 0.68 MAPT (0.55) LCKITKAURKBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK LCK 189/4885ITK 2/4885AURKB 53/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.